Drug Safety
8 articles on Drug Safety, written by Shotlee and medically reviewed for clinical accuracy.
Wegovy and Eye Stroke Risk: What You Need to Know
A recent study has raised questions about a rare but serious eye condition linked to Wegovy. Learn more about ischemic optic neuropathy (ION) and what this research means for patients using GLP-1 medications.
7 min read
Retatrutide Trials: Why Extreme Weight Loss Isn't Always Safe
Clinical trials for the triple-agonist Retatrutide show promising weight loss, but 11% of high-dose participants dropped out due to side effects.
7 min read
FDA requests removal of suicide warning labels from GLP-1 weight-loss medications
The Food and Drug Administration announced on Tuesday its desire to remove suicide warning labels from GLP-1 weight-loss medications. A comprehensive review of 91 trials revealed no heightened risk of suicidal thoughts or behaviors among users compared to placebo groups. This change aligns the labels with those of diabetes equivalents from the same manufacturers.
2 min read
Cutaneous Reactions Rare Yet Differ Among GLP-1 Receptor Agonists
Research on FDA adverse event reports indicates that cutaneous side effects from GLP-1 receptor agonists occur infrequently, with variation depending on the drug. Semaglutide reported the highest rates, while dulaglutide had the lowest. Monitoring and awareness are key for patients using these medications.
3 min read
Are Replicas of Ozempic and Wegovy Safe? Understanding Compounded GLP-1s
Compounded semaglutide medications are custom-made by compounding pharmacies, containing the active ingredient in Ozempic and Wegovy. However, they are not FDA-approved and carry potential risks. This article explains what you need to know about these alternatives.
12 min read
Safety Alert Released for Ozempic and Related GLP-1 Medications
A safety alert has been issued in Australia concerning GLP-1 receptor agonists like Ozempic. The alert highlights a potential connection to suicidal thoughts and a possible reduction in the effectiveness of oral contraceptives.
1 min read
Safety Alert Issued for Ozempic and GLP-1 Receptor Agonists by Watchdog
The Therapeutic Goods Administration (TGA) in Australia has released a safety warning concerning GLP-1 receptor agonists, including Ozempic. The alert highlights potential links to suicidal thoughts and the reduced effectiveness of oral contraceptives.
1 min read
Ozempic-like Medications: New Alert Issued Over Suicidal Thought Risk
Australia's Therapeutic Goods Administration (TGA) has issued a safety alert concerning Ozempic-style drugs and a potential connection to suicidal thoughts and behaviors. While a direct causal link hasn't been established, the TGA advises patients to immediately inform their healthcare provider if they experience any changes in mood or behavior.
4 min read